Search Results - "SANDBAEK, A"

Co-occurrence of Periodontitis and Diabetes-Related Complications by Bitencourt, F.V., Nascimento, G.G., Costa, S.A., Andersen, A., Sandbæk, A., Leite, F.R.M.

“…Periodontitis is a common finding among people with diabetes mellitus (DM) and has been cited as a DM complication. Whether and how periodontitis relates to…”
Get full text

Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus by Jensen, T. M., Vistisen, D., Fleming, T., Nawroth, P. P., Rossing, P., Jørgensen, M. E., Lauritzen, T., Sandbæk, A., Witte, D. R.

“…Aims The glycolysis‐derived metabolite methylglyoxal has been linked to clinical microvascular complications, including diabetic nephropathy. We aimed to…”
Get full text

Periodontitis and Diabetes Complications: A Danish Population-Based Study by Bitencourt, F.V., Andersen, A., Bjerg, L., Sandbæk, A., Li, H., Nascimento, G.G., Spin-Neto, R., Peres, M.A., Leite, F.R.M.

“…Conflicting evidence suggests a link between diabetes-related microvascular complications and periodontitis. Reliable estimates have been hindered by small…”
Get full text

Risk of dementia and cognitive dysfunction in individuals with diabetes or elevated blood glucose by Wium-Andersen, I K, Rungby, J, Jørgensen, M B, Sandbæk, A, Osler, M, Wium-Andersen, M K

“…To determine the risk of dementia in patients with type 1 or type 2 diabetes and in individuals with glycosylated haemoglobin, type A1C (HbA1c) of ⩾48…”
Get full text

Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes: the ADDITION‐Europe trial by Dalsgaard, E.‐M., Sandbæk, A., Griffin, S. J., Rutten, G. E. H. M., Khunti, K., Davies, M. J., Irving, G. J., Vos, R. C., Webb, D. R., Wareham, N. J., Witte, D. R.

“…Aims To present the longer‐term impact of multifactorial treatment of type 2 diabetes on self‐reported health status, diabetes‐specific quality of life, and…”
Get full text

GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes by Sparsø, T, Andersen, G, Nielsen, T, Burgdorf, K. S, Gjesing, A. P, Nielsen, A. L, Albrechtsen, A, Rasmussen, S. S, Jørgensen, T, Borch-Johnsen, K, Sandbæk, A, Lauritzen, T, Madsbad, S, Hansen, T, Pedersen, O

“…Aims/hypothesis Recent genome-wide association studies have suggested that a polymorphism in GCKR, the gene encoding the glucokinase regulatory protein, is…”
Get full text

The role of serum methylglyoxal on diabetic peripheral and cardiovascular autonomic neuropathy: the ADDITION Denmark study by Hansen, C. S., Jensen, T. M., Jensen, J. S., Nawroth, P., Fleming, T., Witte, D. R., Lauritzen, T., Sandbæk, A., Charles, M., Fleischer, J., Vistisen, D., Jørgensen, M. E.

“…Aims Cardiovascular autonomic neuropathy and diabetic peripheral neuropathy are common diabetic complications and independent predictors of cardiovascular…”
Get full text

Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark by Ribe, A R, Laursen, T M, Sandbaek, A, Charles, M, Nordentoft, M, Vestergaard, M

“…Persons with severe mental illness (SMI) have excess mortality, which may partly be explained by their high prevalence of diabetes. We compared the overall and…”
Get more information

The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status by Heraclides, A., Jensen, T. M., Rasmussen, S. S., Eugen-Olsen, J., Haugaard, S. B., Borch-Johnsen, K., Sandbæk, A., Lauritzen, T., Witte, D. R.

“…Aims/hypothesis Recent evidence links the soluble urokinase plasminogen activator receptor (suPAR), a stable biomarker of systemic immune activation, to…”
Get full text

Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial by Tao, L., Wilson, E. C. F., Wareham, N. J., Sandbæk, A., Rutten, G. E. H. M., Lauritzen, T., Khunti, K., Davies, M. J., Borch-Johnsen, K., Griffin, S. J., Simmons, R. K.

“…Aims To examine the short‐ and long‐term cost‐effectiveness of intensive multifactorial treatment compared with routine care among people with screen‐detected…”
Get full text

Variation in prescribing of lipid-lowering medication in primary care is associated with incidence of cardiovascular disease and all-cause mortality in people with screen-detected diabetes: findings from the ADDITION-Denmark trial by Simmons, R. K., Carlsen, A. H., Griffin, S. J., Charles, M., Christiansen, J. S., Borch-Johnsen, K., Sandbæk, A., Lauritzen, T.

“…Aims To examine variation between general practices in the prescription of lipid‐lowering treatment to people with screen‐detected Type 2 diabetes, and…”
Get full text

Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction by Sparsø, T, Grarup, N, Andreasen, C, Albrechtsen, A, Holmkvist, J, Andersen, G, Jørgensen, T, Borch-Johnsen, K, Sandbæk, A, Lauritzen, T, Madsbad, S, Hansen, T, Pedersen, O

“…Aims/hypothesis The list of validated type 2 diabetes susceptibility variants has recently been expanded from three to 19. The variants identified are common…”
Get full text

Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial by Black, J. A., Sharp, S. J., Wareham, N. J., Sandbæk, A., Rutten, G. E. H. M., Lauritzen, T., Khunti, K., Davies, M. J., Borch-Johnsen, K., Griffin, S. J., Simmons, R. K.

“…Aims Little is known about the long‐term effects of intensive multifactorial treatment early in the diabetes disease trajectory. In the absence of long‐term…”
Get full text

Intensive multifactorial treatment modifies the effect of family history of diabetes on glycaemic control in people with Type 2 diabetes: a post hoc analysis of the ADDITION‐Denmark randomized controlled trial by Eliraqi, G. M., Vistisen, D., Lauritzen, T., Sandbæk, A., Jørgensen, M. E., Færch, K.

“…Aim To investigate whether intensive multifactorial treatment can reverse the predisposed adverse phenotype of people with Type 2 diabetes who have a family…”
Get full text

Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study by Charles, M., Fleischer, J., Witte, D. R., Ejskjaer, N., Borch-Johnsen, K., Lauritzen, T., Sandbaek, A.

“…Aims/hypothesis There is limited evidence on how multifactorial treatment improves outcomes of diabetes when initiated in the lead time between detection by…”
Get full text

Screening for Type 2 diabetes. Lessons from the ADDITION-Europe study by van den Donk, M., Sandbaek, A., Borch-Johnsen, K., Lauritzen, T., Simmons, R. K., Wareham, N. J., Griffin, S. J., Davies, M. J., Khunti, K., Rutten, G. E. H. M.

“…Diabet. Med. 28, 1416–1424 (2011) Aims  To describe and compare attendance rates and the proportions of people identified with Type 2 diabetes mellitus in…”
Get full text

Impact of polymorphisms in WFS1 on prediabetic phenotypes in a population-based sample of middle-aged people with normal and abnormal glucose regulation by Sparsø, T, Andersen, G, Albrechtsen, A, Jørgensen, T, Borch-Johnsen, K, Sandbæk, A, Lauritzen, T, Wasson, J, Permutt, M. A, Glaser, B, Madsbad, S, Pedersen, O, Hansen, T

“…Aim/hypothesis Recently, variants in WFS1 have been shown to be associated with type 2 diabetes. We aimed to examine metabolic risk phenotypes of WFS1 variants…”
Get full text

The impact of intensive multifactorial treatment on perceptions of chronic care among individuals with screen-detected diabetes: results from the ADDITION-Denmark trial by Kuznetsov, L, Simmons, R K, Sandbaek, A, Maindal, H T

“…To describe perceptions of chronic care among diabetes patients 6 years after diagnosis by screening and to examine the impact of intensive treatment on…”
Get more information

Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial by Simmons, R. K., Sharp, S. J., Sandbæk, A., Borch-Johnsen, K., Davies, M. J., Khunti, K., Lauritzen, T., Rutten, G. E. H. M., van den Donk, M., Wareham, N. J., Griffin, S. J.

“…Aims  To describe the total cardiovascular burden (cardiovascular morbidity or mortality, revascularization or non‐traumatic amputation) in individuals with…”
Get full text

HbA₁c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark by Skriver, M. V, Borch-Johnsen, K, Lauritzen, T, Sandbaek, A

“…Aims/hypothesis Stepwise screening for type 2 diabetes will not only identify people with the disease or some other form of dysglycaemia (impaired fasting…”
Get full text